Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Quotient Sciences

              • Deals

              Virtual BoothTransforming Drug Development with Science & Innovation.

              UNITED KINGDOM United Kingdom

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              6th Formulation & Drug Delivery

              Attending

              Request a Meeting Now

              Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

              Contact the Supplier

              Lead Product(s): GP1681

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: CytoAgents

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 28, 2020

              Details:

              Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.

              ILC Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              ILC Seeks £4m to Help Advance COVID-19 Trials

              Contact the Supplier

              Lead Product(s): Interferon Alpha 14

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2020

              Details:

              The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.

              Pneumagen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Pneumagen Ltd Announces Positive Anti-Viral Activity for Novel Glycan Approach in Preventing Coronavirus (COVID-19) Infections

              Contact the Supplier

              Lead Product(s): Carbohydrate binding modules

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2020

              Details:

              Pneumagen's mCBMs were found to reduce the number of SARS-CoV-2 plaques when the mCBMs were used in both prevention and treatment of infection.

              Scancell Holdings

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Scancell Kicks Off COVID-19 Vaccine Development

              Contact the Supplier

              Lead Product(s): DNA vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 24, 2020

              Details:

              Scancell has developed DNA vaccines that target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells.

              Stabilitech Biopharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules

              Contact the Supplier

              Lead Product(s): OraPro-COVID-19

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $7.2 million Upfront Cash: Undisclosed

              Deal Type: Funding April 20, 2020

              Details:

              Stabilitech Biopharma is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19.

              Tiziana Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19

              Contact the Supplier

              Lead Product(s): TZLS-501

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              Details:

              Development of this technology is a step forward toward expediting development of TZLS-501, for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.

              Lamellar Biomedical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19

              Contact the Supplier

              Lead Product(s): Lamellasome COVID-19 therapy

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 08, 2020

              Details:

              Inhaled LAMELLASOME™ treatment period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

              Ossianix

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Ossianix is Responding to the COVID-19 Pandemic by Developing Therapeutic Single Domain VNAR Antibodies

              Contact the Supplier

              Lead Product(s): VNAR antibodies

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 02, 2020

              Details:

              A novel approach being pioneered at Ossianix uses its patented VNAR phage display libraries to identify single domain antibodies with high affinity and specificity against the COVID-19 spike protein.

              Cobra Biologics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

              Contact the Supplier

              Lead Product(s): DNA vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Karolinska Institutet

              Deal Size: $3.2 million Upfront Cash: Undisclosed

              Deal Type: Funding March 31, 2020

              Details:

              The funding will leverage phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

              Pneumagen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Pneumagen Leverages its Novel Glycan Approach

              Contact the Supplier

              Lead Product(s): Carbohydrate binding modules

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 17, 2020

              Details:

              Pneumagen has initiated a new programme to prevent and treat COVID-19 infections using its first-in-class Carbohydrate Binding Modules, generated using its proprietary GlycoTarge™ platform.

              PharmaCompass

              PharmaCompass__DigitalAd